CA-DENODO
9.6.2022 09:02:06 CEST | Business Wire | Press release
Denodo , a leader in data management, today released the findings of its sixth annual cloud usage survey which revealed that cloud adoption is continuing its rapid climb, with more than half (54%) of participants stating they are either at an intermediate or advanced level of cloud usage. Cloud-enabled business transformation has become a priority as organizations face global supply chain issues, cybersecurity threats, and geopolitical instability. While organizations of all sizes and vertical markets are turning to the cloud to ensure flexibility and resilience in the face of these challenges, small to medium sized businesses have driven investment in cloud infrastructure services to support workload migration, data storage services, and cloud-native application development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607006385/en/
Download the complimentary findings here .
Cloud-based data warehouses, data lakes, and lake houses played a prominent role in 2021, and was cited as both a top initiative by respondents (48%) and a top use case (57%). Hybrid cloud continues to be the deployment model of choice as it has been since the 2020 survey. However, this year, the gap between hybrid cloud and private cloud is dramatically wider. Hybrid cloud was chosen by almost twice the number of respondents (37.5%), compared with pure public cloud, at 20%. This year, it is clear that hybrid cloud is less a “choice” but a “necessity” and indicates that companies are not completely getting rid of their on-premises systems even if they have increased their cloud footprint. Companies have good reasons for deploying this mixed deployment style, regulatory compliance among them, which may be why they are opting not to simply abandon on-premises systems when the technology landscape changes.
As it relates to these survey respondent companies being data-driven, nearly four in five respondents (79%) cited complexity of data integration, data accessibility, and accommodating different data formats as the primary barrier to becoming data-driven followed by the lack of analytical skills and resources to turn raw data into insights (62%). Data scientists struggled as well. Often cited for spending more time finding, accessing, and preparing data than they do analyzing it, more than 2 out of five (44%) were unable to find, access, and analyze half or more of their data after adopting cloud technologies and only 17% were able to leverage 75% or more of their data.
The role of IT in the cloud modernization journey has also changed. In 2020, the focus for tech professionals was choosing the appropriate cloud provider and managing the migration. But in 2021, these IT teams are more focused on receiving the training needed to take their organization’s cloud systems to the next level (as per 31.3% of survey respondents), while other activities such as selecting cloud provider and planning for cloud migrations still remain important. Companies are using cloud for various use cases with the most popular being reporting and dashboards, and self-service BI and ad-hoc analytics; however, respondents anticipate a shift to data virtualization, data preparation, data quality and blending in the future.
These use cases paint a vivid portrait of where many organizations are with respect to their cloud journeys. First, it reflects the fact that the business stakeholders within organizations are ready to get better use out of their data, and second, it shows that organizations are now looking to maximize their cloud systems with robust cloud-based repositories. Having migrated key workloads to the cloud, the next step for many companies is to find a place to store the new data they then begin to acquire. Modern data-management approaches like logical data fabric enable organizations to seamlessly accommodate legacy systems so that they can work in tandem with cloud systems.
“Audiences continue to express their need for real-time data so it is no surprise that availability, with regard to data integration, management, and analytics in the cloud, is not only ‘nice to have,’ but critical to becoming data-driven,” said Ravi Shankar, senior vice president and chief marketing officer of Denodo. “This is true across all configurations, but the reality is most organizations are unable to find, access, and analyze half or more of their data after adopting cloud technologies. That may be why the overwhelming majority of organizations (93%) stated that they were using, evaluating, or considering leveraging cloud-based data integration, management, and analytics including powerful technologies, such as data virtualization and logical data fabric to provide seamless, real-time access across both on-premises and cloud systems.”
When it comes to choosing cloud service providers, Microsoft Azure and Amazon Web Services (AWS) continue to dominate the market by a wide margin, but this year, AWS (44.6%) has jumped ahead of Azure (26.2%) with a substantial lead, after Azure has kept just ahead of AWS for two consecutive years. Google Cloud Platform (GCP) came in as a third most popular option (8%), according to the survey. In contrast, Alibaba showed a bump from 1.4% in 2021 to 3.6% this year.
Methodology:
The Denodo Global Cloud Survey 2022 surveyed stakeholders at over 150 organizations across 3 major global regions – North America, EMEA, and APAC – to understand where organizations are in their cloud adoption journeys. Surveys were fielded online to data and cloud professionals from various backgrounds and roles in March of 2022. The results from the Denodo Global Cloud Survey 2022 are available for download here .
Please Tweet: https://bit.ly/3Nt7uZ1
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053 / +65 6950 7489.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006385/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom